Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors

HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibit...

Full description

Saved in:
Bibliographic Details
Published inJournal of medicinal chemistry Vol. 54; no. 9; pp. 3393 - 3417
Main Authors Johnson, Ted W, Tanis, Steven P, Butler, Scott L, Dalvie, Deepak, DeLisle, Dorothy M, Dress, Klaus R, Flahive, Erik J, Hu, Qiyue, Kuehler, Jon E, Kuki, Atsuo, Liu, Wen, McClellan, Guy A, Peng, Qinghai, Plewe, Michael B, Richardson, Paul F, Smith, Graham L, Solowiej, Jim, Tran, Khanh T, Wang, Hai, Yu, Xiaoming, Zhang, Junhu, Zhu, Huichun
Format Journal Article
LanguageEnglish
Published WASHINGTON American Chemical Society 12.05.2011
Amer Chemical Soc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:HIV-1 integrase (IN) is one of three enzymes encoded by the HIV genome and is essential for viral replication, and HIV-1 IN inhibitors have emerged as a new promising class of therapeutics. Recently, we reported the synthesis of orally bioavailable azaindole hydroxamic acids that were potent inhibitors of the HIV-1 IN enzyme. Here we disclose the design and synthesis of novel tricyclic N-hydroxy-dihydronaphthyridinones as potent, orally bioavailable HIV-1 integrase inhibitors displaying excellent ligand and lipophilic efficiencies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0022-2623
1520-4804
DOI:10.1021/jm200208d